Introduction 7400 UV/Visible spectrometer using a cell path length of 1cm. Melting points were determined using a Melt John's apparatus and are uncorrected. High performance liquid chromatography (HPLC) was done using a Hewlett Packard 1100 series instrument consisting of an automatic sampler, a electronic degasser, a thermostatic control unit, a diode array detector in conjunction with a chem station software assembly (Pao Alto, Calif., USA). The column used was an analytical RP-18 Lichrospher column (4.6×150 mm) and eluent was 35:65, H 2 O (0.1% ACOH): ACN. The flow rate was maintained at 1.0 ml/min and the detection wavelength was set at 275nm. The column was maintained at room temperature throughout the analysis. Elemental analysis was performed by Atlantic Microlabs (Norcross, Ga., USA). Column chromatography was done using silica gel obtained from the Baker Company (Gibbs Town, NJ, USA). The solvents used for elution varied depending on the compound and included either one or a combination of the following: ethylacetate, methanol, chloroform, hexane, methylene chloride, tetrahydrofuran and ether.
Compounds 1-4 and 7 were made by condensing naphthylethylamines and thiocarbaimidazole derivatives of 5 and 6′, substituted amino pyridines in anhydrous dimethylformamide (Scheme 1). The chiral (R and S) naphthyl amines were purchased from Aldrich and were used without further purification. Thiazolyl and benzothiazolyl substituted thioureas were prepared in a similar way using thiocarbaimidazole derivatives of either substituted amino thiazoles or benzothiazoles respectively.
In brief, Scheme 1 involved the addition of thiocarbonyl imidazole and 2-amino -5-halo pyridine to 100 ml of dry acetonitrile under nitrogen atmosphere, stirring at room temperature for 12-15 h. The precipitate was filtered, washed with cold acetonitrile, and dried thoroughly under vacuum to yield the thiocarbonyl intermediate. In the subsequent step, these intermediates were taken up in a dry flasks under nitrogen, 50 ml of anhydrous dimethylformamide was added, and the contents were stirred for 30min at room temperature. We then added to this solution the appropriate chiral naphthyl amines dissolved in 10ml of dry dimethylformamide and heated the reaction mixture to 110°C over an oil bath for 15 h. After this period, the reaction mixture was cooled to room temperature and poured into crushed ice/water mixture, and the contents were stirred for an additional hour. The precipitate was filtered, washed with cold water several times and dried under vacuum. The dried precipitate was then dissolved in chloroform and washed with brine, water, and finally the separated chloroform layer was dried over anhydrous magnesium sulfate. Filtration and evaporation of the solvent yielded the target thiourea compound. Compounds were further purified using silica gel column chromatography and finally recrystallized using ethanol as solvent. A similar procedure was followed for other substituted compounds using either thiazolyl or benzothiazolyl precursors.
Stock HTLV IIIB virus
The HIV-1 strain HTLV IIIB , propagated in CCRF-CEM TK Venkatachalam et al.
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Scheme 1 cells, was used for in vitro assays of the anti-HIV-1 activity of the synthesized thiourea derivatives. Cell free supernatants of HTLV IIIB infected CCRF-CEM cells were harvested, dispensed into 1 ml aliquots, and frozen at -70°C. Periodic titration of stock virus was performed by examining its cytopathic effects in MT-2 cells .
In vitro assays of anti-HIV-1 activity
Normal human peripheral blood mononuclear cells (PBMC) from HIV-negative donors were cultured for 72 h in RPMI 1640 supplemented with 20% (v/v) heat inactivated fetal bovine serum, 3% interleukin-2, 2 mM L-glutamine, 25 mM HEPES, 2 g/l NaHCO 3 , 50 µg/ml gentamicin, and 4 µg/ml phytohaemagglutinin prior to exposure to HIV-1 at a multiplicity of infection (m.o.i.) of 0.1 during a 1-h adsorption period at 37°C in a humidified 5% CO 2 atmosphere. Subsequently, cells were cultured in 96-well microtiter plates (100 µl; 2×10 6 cells/ml) in the presence of various concentrations of thiourea analogues or zidovudine, and aliquots of culture supernatants were removed from the wells on the seventh day after infection for p24 antigen assays, as previously described . The applied p24 enzyme immunoassay was the unmodified kinetic assay commercially available from Coulter Corporation/Immunotech (Westbrooke, Me., USA), which uses a murine mAb to HIV core protein coated onto microwell strips, to which the antigen present in the test culture supernatant samples binds. Percent viral inhibition was calculated by comparing the p24 values from untreated infected cells (that is, virus controls). In addition, the IC 50 values measuring the activity of compounds against recombinant HIV-1 RT were determined using the Quant-RT assay system (Amersham, Arlington Heights, Ill., USA), which uses the scintillation proximity assay Principle . 3, 152.2, 143.9, 138.9*, 133.5, 130.4, 128.8, 127.8, 126.5, 125.8*, 123.9, 123.2, 122.8, 114.2, 50.5, 21.5; IR ν 3448, 3239, 3162, 3039, 2966 IR ν 3448, 3239, 3162, 3039, , 1598 IR ν 3448, 3239, 3162, 3039, , 1527 IR ν 3448, 3239, 3162, 3039, , 1490 IR ν 3448, 3239, 3162, 3039, , 1188 152.8, 144.6, 139.5*, 134.1, 131.0, 129.4, 128.4, 127.1, 126.5, 126.3, 124.5, 123.8, 123.5, 114.8, 51.1, 22.2; IR ν 3448, 3236, 3160, 3091, 3027, 2975 IR ν 3448, 3236, 3160, 3091, 3027, , 1598 IR ν 3448, 3236, 3160, 3091, 3027, , 1527 IR ν 3448, 3236, 3160, 3091, 3027, , 1475 IR ν 3448, 3236, 3160, 3091, 3027, , 1188 152.5, 146.2, 141.5, 138.8, 133.5, 130.4, 128.8, 127.8, 126.5, 125.8, 125.7, 123.2, 121.9, 114.7, 112.0, 50.5, 21.6; IR ν 3442, 3241, 3158, 3022, 2964 IR ν 3442, 3241, 3158, 3022, , 2921 IR ν 3442, 3241, 3158, 3022, , 1592 IR ν 3442, 3241, 3158, 3022, , 1556 IR ν 3442, 3241, 3158, 3022, , 1525 IR ν 3442, 3241, 3158, 3022, . 1189 152.5, 146.2, 141.5, 138.8, 133.5, 130.4, 128.8, 127.8, 126.5, 125.8, 125.7, 123.2, 122.8, 114.7, 112.1, 50.5, 21.6; IR ν 3455, 3239, 3158, 3022, 2975 IR ν 3455, 3239, 3158, 3022, , 1592 IR ν 3455, 3239, 3158, 3022, , 1525 IR ν 3455, 3239, 3158, 3022, , 1465 IR ν 3455, 3239, 3158, 3022, , 1189 5, 152.0, 144.9, 139.9, 139.1, 133.6, 130.6, 128.9, 127.9, 127.0, 126.6, 125.8*, 123.4, 122.9, 112.4, 50.5, 21.6, 17.4; IR ν 3440, 3232, 3027, 2969 IR ν 3440, 3232, 3027, , 1600 IR ν 3440, 3232, 3027, , 1562 IR ν 3440, 3232, 3027, , 1492 IR ν 3440, 3232, 3027, , 1195 4, 152.0, 144.9, 139.9, 139.1, 133.6, 130.6, 128.9, 127.8, 127.0, 126.5, 125.8*, 123.4, 122.9, 112.4, 50.4, 21.6, 17.4; IR ν 3232, 3027, 2969 IR ν 3232, 3027, , 1600 IR ν 3232, 3027, , 1527 IR ν 3232, 3027, , 1195 : 5.96, N: 13.07; found: C: 70.84, H: 5.99, N: 13.16 . 6, 154.2, 153.4, 139.3*, 133.6, 130.5, 128.9, 127.9, 126.6, 125.8*, 123.3, 122.9, 117.0, 109.6, 50.3, 23.6, 21.6; IR ν 3433, 3190, 3043, 2923 IR ν 3433, 3190, 3043, , 1612 IR ν 3433, 3190, 3043, , 1538 IR ν 3433, 3190, 3043, , 1454 IR ν 3433, 3190, 3043, , 1226 162.0, 139.4, 134.1, 131.0, 129.4, 128.4, 127.1, 126.5, 126.2, 123.8, 123.4, 106.8, 50.6, 21.8, 17.3; IR ν 3423, 3170, 3018, 2968 IR ν 3423, 3170, 3018, , 1581 IR ν 3423, 3170, 3018, , 1531 IR ν 3423, 3170, 3018, , 1502 IR ν 3423, 3170, 3018, , 1205 138.7, 133.5, 130.4, 128.8, 127.8, 126.5, 125.8, 125.6, 123.2, 122.8, 106.2, 49.9, 21.2, 16.7; IR ν 3448, 3170, 3020, 2969 IR ν 3448, 3170, 3020, , 1581 IR ν 3448, 3170, 3020, , 1531 IR ν 3448, 3170, 3020, , 1502 IR ν 3448, 3170, 3020, , 1207 161.8, 138.5, 133.5, 130.6, 128.8, 127.9, 126.6, 125.9, 125.6, 125.5, 123.2, 122.8, 112.3, 49.8, 20.9; IR ν 3423, 3174, 3035, 1569 IR ν 3423, 3174, 3035, , 1508 IR ν 3423, 3174, 3035, , 1297 IR ν 3423, 3174, 3035, , 1188 5, 156.7, 153.5, 150.1, 139.1, 133.5, 130.4, 128.8, 127.7, 126.5, 125.8, 125.6, 123.2, 122.7, 118.2, 109.4, 50.2, 23.3, 21.6, 20.9; IR ν 3201, 3039, 2969 IR ν 3201, 3039, , 1619 IR ν 3201, 3039, , 1535 IR ν 3201, 3039, , 1203 MALDI-TOF m/z 337.3 (C 20 : 6.31, N: 12.53; found: C: 71.73, H: 6.28, N: 12.60 . -[2-(4,6-dimethylpyridyl 6, 153.7, 153.5, 150.0, 139.1, 133.5, 130.4, 128.8, 127.7, 126.5, 125.8, 125.6, 123.2, 122.7, 118.2, 109.4, 50.2, 23.3, 21.6, 20.9; IR ν 3425, 3212, 3039, 2969 IR ν 3425, 3212, 3039, , 1623 IR ν 3425, 3212, 3039, , 1535 IR ν 3425, 3212, 3039, , 1211 MALDI-TOF m/z 336.8 (C 20 5, 169.7, 160.8, 143.3, 138.7, 133.5, 130.4, 128.8, 127.8, 126.5, 125.9, 125.6, 123.1, 122.7, 109.4, 60.5, 49.9, 36.6, 21.3, 14.3; IR ν 3463, 3166, 2981 IR ν 3463, 3166, , 1743 IR ν 3463, 3166, , 1573 IR ν 3463, 3166, , 1535 IR ν 3463, 3166, , 1508 IR ν 3463, 3166, , 1380 IR ν 3463, 3166, , 1211 IR ν 3463, 3166, , 1164 ; MALDI-TOF m/z 401.2 (C 20 H 21 N 3 O 2 S 2 + 2H + ); HPLC R t : 9.89 min.% Purity 99.9, elemental analysis: calculated: C: 60.13, H: 5.30, N: 10.52; found: C: 60.40, H: 5.36, N: 10.53 . [2-(ethyl-4-acetylthiazolyl) ]thiourea (8S). mp 107-109°C; 1 H NMR (DMSOd 6 ) δ 11.54 (s, 1 H), 10.10 (s, 1 H), 8.15 (t, 1 H), 7.96 (t, 1 H), 7.86 (t, 1 H), 7.61-7.50 (m, 4 H), 6.89 (s, 1 H), 6.21 (s, 1 H), 4.05-4.00 (m, 2 H), 3.64 (s, 2 H), 1.62 (d, 3 H, J=3.9 Hz), 1.16-1.09 (m, 3 H); 13 C NMR (DMSO-d 6 ) δ 177. 2, 170.3, 161.5, 143.9, 139.3, 134.1, 131.0, 129.4, 128.4, 127.2, 126.5, 126.2, 123.7, 123.3, 109.9, 61.1, 50.5, 31.2, 21.9, 14.9; IR ν 3444, 3185, 3047, 2927 IR ν 3444, 3185, 3047, , 1577 IR ν 3444, 3185, 3047, , 1554 IR ν 3444, 3185, 3047, , 1519 IR ν 3444, 3185, 3047, , 1230 6, 161.6, 138.6, 133.5, 130.5, 128.8, 127.9, 126.5, 126.3, 125.9, 125.6, 123.6, 123.2, 121.8, 118.950.2, 50.1, 21.1; IR ν 3563, 3182, 3039, 2973 IR ν 3563, 3182, 3039, , 1565 IR ν 3563, 3182, 3039, , 1523 IR ν 3563, 3182, 3039, , 1199 ; MALDI-TOF m/z 367.2 (C 20 H 17 N 3 S 2 + 4H + ); HPLC R t : 18.84 min.% Purity 99.7, elemental analysis: calculated: C: 66. 09, H: 4.71, N: 11.56; found: C: 65.89, H: 4.75, N: 11.36 . 3, 162.4, 139.2, 134.1, 131.1, 129.4, 128.5, 127.2, 126.9, 126.5, 126.3, 124.3, 123.8, 123.5, 122.4, 119.7, 50.8, 21.7; IR ν 3452, 3166, 3031, 1573 IR ν 3452, 3166, 3031, , 1523 IR ν 3452, 3166, 3031, , 1203 9, 160.2, 147.7, 138.4, 133.5, 130.5, 129.6, 129.1, 128.8, 127.9, 126.9, 126.6, 125.9, 125.6, 123.8, 123.0, 122.7, 119.2, 50.0, 30.9, 20.9, 17.7; IR ν 3506, 3014, 1560 IR ν 3506, 3014, , 1523 IR ν 3506, 3014, , 1201 ; MALDI-TOF m/z 378.9 (C 21 H 19 N 3 S 2 + 2H + ); HPLC R t : 30.49 min. % Purity 99.5, elemental analysis: calculated: C: 66.81, H: 5.07, N:11.13; found: C: 66.94, H: 5.20, N: 11.26 . 8, 160.1, 147.7, 138.4, 133.5, 130.5, 129.6, 129.0, 128.8, 127.9, 126.9, 126.6, 125.9, 125.6, 123.9, 123.0, 122.8, 119.2, 49.9, 20.9, 17.7; IR ν 3425, 3014, 1554 IR ν 3425, 3014, , 1523 MALDI-TOF m/z 380.4 (C 21 N:11.13; found: C: 66.73, H: 5.08, N: 11.16 . The anti-HIV activity was measured by determining the inhibition of the HIV-1 strain HTLV IIIB in human peripheral blood mononuclear cells as previously described in detail (Zarling et al., 1990) . The cell-free reverse transcriptase (RT) inhibition assays using recombinant reverse transcriptase (rRT) and the Quan-RT assay kit (Amersham, Arlington Heights, Ill., USA) were performed as reported (Zarling et al., 1990) . The anti-HIV activity was measured by determining the inhibition of the replication of the indicated HIV-1 strains and clinical HIV-1 isolates in human peripheral blood mononuclear cells (Uckun et al., ,b, 2000a . Table 2 . Activity of lead chiral naphthyl thiourea compounds against drug-resistant HIV-1 laboratory strains and primary HIV-1 isolates for AIDS patients strains than the standard NNI nevirapine (Viramune), notably, the lead compounds (Table 2) . Also, the lead CNT compounds exhibited potent anti-HIV activity against primary HIV-1 isolates from AIDS patients with average IC 50 values ranging from 1 to 11 nM (Table 2) . Our molecular modelling studies indicated that the 'R' stereoisomer of the CNT compound 5 (compound 5R) would fit the target NNI binding pocket on HIV-RT much better than its enantiomer compound 5S (Figure 1) . Unfavourable steric interactions with the NNI binding pocket residues near the Y181 side chain would impair the binding of the 'S' stereoisomer in lower energy 'staggered' conformation. This steric hindrance could be relieved if compound 5S would adopt a energetically unfavorable 'eclipsed' conformation. In either case, the estimated bind-ing energies would be significantly higher for compound 5S than its enantiomer. Similar assumptions could be made in favor of the 'R' stereoisomers of all 11 CNT compounds, with pyridyl rings or thiazolyl rings, included in the present study (Table 1 ). These predictions from the modelling studies are consistent with the experimental data obtained in cell-free RT inhibition assays and cellular HIV inhibition assays.
Physical constants N -[ 1 -( 1 R ) -( N a p h t h y l ) e t h y l ] -N ′ -[ 2 -( 5 -c h l o r o -

N -[ 1 -( 1 R ) -( N a p h t h y l ) e t h y l ]
-N ′ -[ 2 -( 5 -b r o m o - pyridyl)]thiourea (2R
N -[ 1 -( 1 S ) -( N a p h t h y l ) e t h y l ]
-N ′ -[ 2 -( 5 -b r o m o - pyridyl)]thiourea (2S
N -[ 1 -( 1 R ) -N a p h t h y l e t h y l ]
-N ′ -[ 2 -( 5 -m e t h y l - pyridyl)]thiourea (3R
N -[ 1 -( 1 S ) -N a p h t h y l e t h y l ]
-N ′ -[ 2 -( 5 -m e t h y l - pyridyl)]thiourea (3SN-[1-(1R)-Naphthylethyl]-N′-[2-(6-methyl-pyridyl)] thiourea (4R
N -[ 1 -( 1 S ) -N a p h t h y l e t h y l ] -N
N -[ 1 -( 1 S ) -( N a p h t h y l ) e t h y l ] -N ′ -[ 2 -( 4 -m e t h y lthiazolyl)]thiourea (5S
N-[1-(1R)-(1-Naphthyl)ethyl]-N′
N-[1-(1S)-(1-Naphthyl)ethyl]-N′-
In summary, our data establish the stereochemistry as a major determinant of the potency of this new class of NNI. The toxicity and pharmacodynamic features of the CNT compounds will be the subject of a separate study. It will be important to determine if in vitro active concentrations of these compounds can be achieved in vivo without unacceptable toxicity. Our recent studies indicate that this goal can be accomplished with other thiourea compounds synthesized by our group (Chen et al., 1999 (Chen et al., , 2001 . The stick models (green) of 5R (R isomer, top) and 5S (S isomer, bottom) were docked into the NNRTI binding site as lower energy staggered conformations with respect to the naphthyl and methyl groups on the chiral carbon. Only the R isomer (5R) provided a suitable fit into the NNRTI binding pocket. The S isomer (5S) formed unfavorable steric interactions with binding pocket residues near the Y181 sidechain.
